Poly Medicure Falls to 52-Week Low of Rs.1822 Amid Market Pressure

7 hours ago
share
Share Via
Poly Medicure has reached a new 52-week low of Rs.1822, marking a significant decline in its stock price amid broader market fluctuations and sector-specific pressures. The stock has experienced a sustained downward trend over the past several days, reflecting a challenging period for the healthcare services company.



Recent Price Movement and Market Context


On 18 Dec 2025, Poly Medicure's share price touched Rs.1822, the lowest level recorded in the past year. This decline comes after four consecutive days of losses, during which the stock has returned -3.29%. The day’s performance showed a further dip of 1.42%, underperforming its sector by 0.35%. The stock is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a sustained bearish momentum.


In contrast, the broader market index, Sensex, opened flat and traded marginally lower by 0.02% at 84,542.92 points. The Sensex remains close to its 52-week high of 86,159.02, just 1.91% away, and is supported by bullish moving averages with the 50-day average positioned above the 200-day average. This divergence highlights the relative weakness in Poly Medicure’s stock compared to the overall market.



Performance Comparison Over One Year


Over the last twelve months, Poly Medicure’s stock has declined by 32.98%, a stark contrast to the Sensex’s positive return of 5.44% and the BSE500’s modest gain of 2.11%. This underperformance is notable given the company’s sector, healthcare services, which has generally shown resilience. The stock’s 52-week high was Rs.2936.7, underscoring the extent of the recent price correction.




Turnaround taking shape! This Small Cap from NBFC sector just hit profitability with strong business fundamentals showing up. Catch it before the major breakout happens!



  • - Recently turned profitable

  • - Strong business fundamentals

  • - Pre-breakout opportunity


Catch the Breakout Early →




Financial Metrics and Valuation Insights


Poly Medicure’s financial data reveals a mixed picture. The company reported flat results in the September 2025 quarter, which may have contributed to the subdued market sentiment. Its dividend payout ratio stands at 10.70%, one of the lowest in its peer group, potentially reflecting a conservative approach to shareholder returns.


The company’s debtors turnover ratio for the half-year period is 4.02 times, indicating the frequency with which receivables are collected. This figure is relatively low, suggesting a slower conversion of sales into cash compared to industry standards. However, the company maintains a low average debt-to-equity ratio of zero, signalling minimal reliance on borrowed funds and a conservative capital structure.


Return on equity (ROE) is recorded at 12.4%, which, while positive, is accompanied by a price-to-book value ratio of 6.4. This valuation metric suggests that the stock is priced at a premium relative to its book value, which may be considered expensive in the context of its recent price performance. The company’s price-to-earnings-to-growth (PEG) ratio stands at 2.3, reflecting the relationship between its valuation, earnings growth, and market expectations.



Sector Position and Market Capitalisation


With a market capitalisation of approximately Rs.18,758 crore, Poly Medicure is the second-largest company in the healthcare services sector, trailing only behind Lenskart Solutions. It accounts for 17.73% of the sector’s total market value, underscoring its significant presence. The company’s annual sales of Rs.1,712.13 crore represent 15.86% of the industry’s total revenue, highlighting its substantial operational scale within the sector.



Institutional Holdings and Market Dynamics


Institutional investors hold 23.31% of Poly Medicure’s shares, indicating a notable level of interest from entities with extensive resources and analytical capabilities. This level of institutional ownership often reflects a degree of confidence in the company’s fundamentals, despite recent price movements.




Is Poly Medicure your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!



  • - Better alternatives suggested

  • - Cross-sector comparison

  • - Portfolio optimization tool


Find Better Alternatives →




Summary of Key Factors Influencing Stock Performance


The recent decline in Poly Medicure’s stock price to its 52-week low can be attributed to a combination of factors. The flat quarterly results and relatively low dividend payout ratio may have tempered investor enthusiasm. Additionally, the company’s slower receivables turnover and premium valuation metrics have likely contributed to cautious market sentiment.


Despite these challenges, Poly Medicure’s strong market position within the healthcare services sector and its low debt levels provide a foundation of stability. The stock’s underperformance relative to the broader market and sector indices highlights the need for close monitoring of future financial disclosures and market developments.



Market Outlook and Broader Context


While the Sensex continues to trade near its 52-week high supported by positive moving averages, Poly Medicure’s stock remains under pressure. The divergence between the company’s share price trajectory and the broader market indices underscores sector-specific and company-specific dynamics at play.


Investors and market participants will be observing upcoming financial results and sector trends closely to assess any shifts in the company’s performance metrics and valuation parameters.






{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News